Co-Diagnostics, Inc. Common Stock
$ 1.38
-4.83%
14 Apr - close price
- Market Cap 5,223,600 USD
- Current Price $ 1.38
- High / Low $ 1.50 / 1.38
- Stock P/E N/A
- Book Value 9.85
- EPS -35.25
- Next Earning Report 2026-05-14
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.44 %
- ROE -1.26 %
- 52 Week High 46.50
- 52 Week Low 1.35
About
Co-Diagnostics, Inc., a molecular diagnostic company, develops, manufactures, and sells reagents used for diagnostic tests that function by detecting and / or analyzing nucleic acid molecules. The company is headquartered in Salt Lake City, Utah.
Analyst Target Price
$45.00
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-19 | 2025-11-13 | 2025-08-14 | 2025-05-07 | 2025-03-12 | 2024-11-07 | 2024-08-08 | 2024-05-09 | 2024-03-14 | 2023-11-09 | 2023-08-10 | 2023-05-11 |
| Reported EPS | -4.4388 | -0.16 | -0.23 | -0.2574 | -0.3778 | -0.32 | -0.14 | -0.31 | -0.5 | -0.2 | -0.31 | -0.2 |
| Estimated EPS | -0.13 | -0.16 | -0.66 | -0.33 | -0.34 | -0.33 | -0.34 | -0.21 | -0.2 | -0.29 | -0.24 | -0.22 |
| Surprise | -4.3088 | 0 | 0.43 | 0.0726 | -0.0378 | 0.01 | 0.2 | -0.1 | -0.3 | 0.09 | -0.07 | 0.02 |
| Surprise Percentage | -3314.4615% | 0% | 65.1515% | 22% | -11.1176% | 3.0303% | 58.8235% | -47.619% | -150% | 31.0345% | -29.1667% | 9.0909% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-14 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -3.6 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: CODX
2026-02-09 14:00:00
Co-Diagnostics, Inc. announced its participation in the World Health Expo Labs Dubai from February 10-13, 2026, where it will showcase its Co-Dx™ PCR platform. This exhibition follows the formation of its joint venture, CoMira Diagnostics, aimed at localizing manufacturing and distribution of Co-Diagnostics' technology in the Middle East and North Africa region. The event provides a key opportunity for the company to engage stakeholders and expand access to high-quality molecular diagnostics, including its PCR platform currently in U.S. clinical studies.
2026-02-09 13:59:10
Co-Diagnostics (OTC: CODX) is set to exhibit its Co-Dx PCR platform at the World Health Expo Labs Dubai from February 10–13, 2026. This participation follows the formation of CoMira Diagnostics, a joint venture aimed at localizing manufacturing and distribution across Saudi Arabia and 18 other MENA countries. The event offers Co-Dx an opportunity to engage with regional stakeholders and advance its strategy to expand access to high-quality molecular diagnostics in the Middle East and North Africa.
2026-02-09 13:59:10
Co-Diagnostics, Inc. announced its participation in the World Health Expo Labs Dubai from February 10-13, 2026, where it will showcase its Co-Dx PCR platform. This follows the formation of its joint venture, CoMira Diagnostics, in Saudi Arabia, aimed at expanding access to molecular diagnostics in the Middle East and North Africa. The company's PCR platform is currently undergoing clinical studies in the United States and is not yet available for sale, pending regulatory review.
2026-02-07 01:28:10
Co-Diagnostics' joint venture, CoSara Diagnostics Pvt. Ltd., has received ISO 13485:2016 certification for its manufacturing facility in Vadodara, India. This certification validates the quality management system and is a crucial step for regulatory submissions of their upcoming PCR platform and associated tests. The certification also positions CoSara to potentially qualify for India's 'Make in India' initiative, offering cost advantages for in-country production.
2026-02-06 13:58:29
Co-Diagnostics' joint venture, CoSara Diagnostics Pvt. Ltd., has received a CDSCO license to manufacture its PCR Pro instrument in India. While this is a significant step towards commercialization, the accompanying PCR test kits for diseases like tuberculosis (MTB) and human papillomavirus (HPV) still require separate regulatory clearance before they can be sold. The license allows CoSara to manufacture and distribute the CoSara-branded PCR Pro instrument in India, making it the final instrument approval needed for commercialization in the country.
2026-02-05 14:30:21
Co-Diagnostics' joint venture, CoSara Diagnostics Pvt. Ltd., has secured a license from the Central Drugs Standard Control Organization (CDSCO) to manufacture and sell the CoSara PCR Pro™ real-time PCR point-of-care instrument in its Ranoli, India facility. This license is a crucial step towards commercializing the PCR Pro instrument and facilitating future regulatory clearance for CoSara PCR test kits for diseases like Mycobacterium tuberculosis (MTB) and human papillomavirus (HPV). The collaboration aims to increase the accessibility of gold-standard PCR diagnostics in underserved areas.
